| dc.contributor.author | Ergun, Sercan | |
| dc.contributor.author | UĞURLU, Serdal | |
| dc.contributor.author | Cetin, Arya | |
| dc.contributor.author | Gursoy, Yahya Kerem | |
| dc.contributor.author | Egeli, Bugra Han | |
| dc.date.accessioned | 2021-12-10T12:24:32Z | |
| dc.date.available | 2021-12-10T12:24:32Z | |
| dc.identifier.citation | Egeli B. H. , Ergun S., Cetin A., Gursoy Y. K. , UĞURLU S., "Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study", CLINICAL RHEUMATOLOGY, 2021 | |
| dc.identifier.issn | 0770-3198 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_babc5cb8-b709-4205-90cf-482d3bb9f290 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/173819 | |
| dc.identifier.uri | https://doi.org/10.1007/s10067-021-05871-9 | |
| dc.description.abstract | Background Idiopathic inflammatory myopathies (IIM) are essentially treated aiming to improve muscle function and extra muscular disease manifestations. Rituximab is potentially a glucocorticoid-sparing agent which was reviewed in multiple studies with small sample sizes due to the rarity of the disease. Higher statistical power can enhance the trustworthiness of alternative treatment modalities yielding the main objective of this study. | |
| dc.language.iso | eng | |
| dc.subject | İmmünoloji ve Romatoloji | |
| dc.subject | Rheumatology | |
| dc.subject | Health Sciences | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ROMATOLOJİ | |
| dc.title | Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study | |
| dc.type | Makale | |
| dc.relation.journal | CLINICAL RHEUMATOLOGY | |
| dc.contributor.department | İstanbul Üniversitesi-Cerrahpaşa , , | |
| dc.contributor.firstauthorID | 2707228 | |
